Gynecological Cancer Articles & Analysis
15 news found
The data were presented during poster sessions at the 34th Symposium on Molecular Targets and Cancer Therapeutics hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR) in Barcelona, Spain. “These early ...
(“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing novel treatments for breast and gynecologic cancers, announced preliminary Phase 2 data from the ongoing SMILE trial of onapristone extended release (ONA-XR), the company’s novel, first-in-class, potent, orally administered progesterone receptor ...
“Onconova’s upcoming Phase 1/2a trial has been thoughtfully designed to explore narazaciclib’s potential as a best-in-class therapy when combined with letrozole in recurrent LGEEC,” said Bhavana Pothuri, MD, Professor, Department of Obstetrics and Gynecology at NYU Grossman School of Medicine and Director, Gynecologic Oncology Research; ...
(Nasdaq: LIXT), notes findings by a team of physician-scientists led by principal investigator Dr. Amir Jazaeri, professor of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, and reported at the annual meeting of Society of Gynecologic Oncology (SGO) in Phoenix, AZ, that a subset of patients ...
(NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will present an analysis based on the June 10th, 2021 data cut from the expansion cohort of the Company’s Phase 1 trial of upifitamab rilsodotin (UpRi) at ...
(“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that five abstracts have been selected for poster or symposium presentations at the American Association for Cancer Research (AACR) ...
The published article on the study, Treatment of intermediate-risk prostate cancer with Cs-131: Long-term results from a single institution, was authored by Joshua L. ...
Hard-to-detect cancers like glioblastoma can have survival rates in the single-digit percentages and require elaborate techniques to detect, treat, and monitor. ...
HCA Florida Healthcare’s Kendall Regional Medical Center, AdventHealth Celebration and The Women’s Hospital at Jackson Memorial now offer first-ever surgical robot with humanoid-shaped arms for use in transvaginal gynecological procedures Previously announced proposed business combination with MedTech Acquisition Corporation (Nasdaq: MTAC) anticipated to close in first quarter of ...
Company to showcase first and only FDA-authorized surgical robot that features miniature humanoid-shaped arms and host in-booth surgeons to discuss their experiences with Hominis Tel Aviv, Israel and Fort Lauderdale, FL, November 11, 2021 – Memic Innovative Surgery (Memic), a medical device company dedicated to transforming healthcare with its proprietary surgical robotic technology, ...
Introduction Anliprogestins have demonstrated promising activity against breast and gynecological cancers, but liver-related safety concerns limited the advancement of this therapeutic class. ...
In a first-of-its-kind procedure in Belgium, Dr. Jan Baekelandt of Bonheiden’s Imelda Hospital has performed a transvaginal robotic-assisted hysterectomy using Memic’s Hominis® technology. Dr. Baekelandt is a pioneering expert in gynecological oncology, and endoscopic and robotic surgery. His research focuses on transvaginal natural orifice transluminal endoscopic surgery ...
Theragenics Corporation, a medical device company serving the cancer treatment market, will provide sales and marketing for C4 Imaging’s novel, Orion Positive-Signal HDR MRI Lumen Marker. The marker is used prior to high dose rate (HDR) brachytherapy to accurately locate the position of the applicators that guide the placement of radioactive sources for the treatment of ...
FDA 510(k) clearance for removal of soft tissue by vaporization offers additional utility for surgeons ROSWELL, Ga. – May 1, 2013 – Plasma Surgical, creator of the PlasmaJet®, an advanced energy medical device designed as a safe and effective alternative to traditional electrosurgery instruments, announced today that it has received 510(k) clearance from the U.S. Food and Drug ...
The donation will be capped at US$10,000. Ovarian cancer is the leading cause of death from gynecologic cancers in the United States and is the fifth leading cause of cancer deaths among U.S. women. ...